(Circulation. 1999;99:1230-1235.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
From the Departments of Cardiology (U.I., K.S.) and Clinical Immunology (M.I., S.M.), Jichi Medical School, Minamikawachi, Tochigi, Japan.
Correspondence to Uichi Ikeda, MD, PhD, Department of Cardiology, Jichi Medical School, Minamikawachi-Machi, Tochigi 329-04, Japan. E-mail uikeda{at}jichi.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and ResultsWe investigated the effects of homocysteine on NO synthesis by measuring the production of nitrite, a stable metabolite of NO, in cultured rat vascular smooth muscle cells (VSMCs). Incubation of cultures with interleukin (IL)-1ß 10 ng/mL for 24 hours caused a significant increase in nitrite generation. The IL-1ßinduced nitrite production by VSMCs was significantly increased by homocysteine in a dose-dependent manner. This effect of homocysteine was significantly inhibited in the presence of NG-monomethyl-L-arginine or actinomycin D. The homocysteine-induced nitrite production was accompanied by increased inducible NO synthase mRNA and protein accumulation. Cysteine, glutathione, or hydrogen peroxide also increased nitrite accumulation in IL-1ßstimulated VSMCs. Coincubation with the radical scavenger catalase or superoxide dismutase markedly reduced homocysteine-induced nitrite accumulation.
ConclusionsHomocysteine enhances NO synthesis in IL-1ßstimulated VSMCs, and oxidative products are involved in the effect of homocysteine.
Key Words: homocysteine interleukins nitric oxide muscle, smooth free radicals
| Introduction |
|---|
|
|
|---|
Homocysteinemia caused by homozygous cystathionine ß-synthase deficiency is associated with an increased incidence of vascular thrombosis and development of arteriosclerosis,8 9 10 and elevated plasma homocysteine levels have been reported to be an independent risk factor for vascular disease.11 12 13 14 15 Furthermore, the administration of homocysteine caused vascular injury and thrombosis in animals.16 The mechanisms by which homocysteinemia leads to thrombosis and arteriosclerosis have not been completely defined. Recent studies using cell culture systems have shown that homocysteine enhances endothelial cellassociated factor V activity17 and inhibits both thrombomodulin surface expression and protein C activation.18 19 20 We also reported that homocysteine inhibited expression of the anticoagulant heparan sulfate in endothelial cells.21 In addition to its effect on endothelial cells, Tsai et al22 recently reported that homocysteine increased DNA synthesis in VSMCs and induced their proliferation. However, the effects of homocysteine on the production of NO, another modulator of vascular function and proliferation, by the vascular smooth muscle have been less well studied.23 Therefore, in this study, we investigated the effects of homocysteine on NO synthesis in cultured rat VSMCs.
| Methods |
|---|
|
|
|---|
2x107 U/mg) was a gift from Otsuka Pharmacy
(Tokushima, Japan). A mouse macrophage iNOS cDNA probe was a
gift from Dr Kawahara (Kobe University School of Medicine, Hyogo,
Japan).4 A monoclonal anti-mouse iNOS antibody, which
cross-reacts with rat iNOS, was obtained from Transduction Laboratory.
Homocysteine, cysteine, glutathione, and hydrogen peroxide were
purchased from Nacalai Tesque Inc.
NG-Monomethyl-L-arginine
(L-NMMA) and actinomycin D were from Sigma Chemical Co. Superoxide
dismutase and catalase were from Seikagaku Kogyo. All other chemicals
used were of the highest grade commercially available.
Cell Culture
Primary cultures of VSMCs were obtained from the media of
thoracic aortas of Sprague-Dawley rats (200 to 250 g), as
described previously.24 The cells were grown in DMEM
supplemented with 10% FCS, 100 U/mL penicillin, and 100 µg/mL
streptomycin. The cultures were harvested twice a week by treatment
with 0.125% trypsin and passaged at a 1:3 ratio in 100-mm culture
dishes. A typical experiment was performed with cultured cells at
passage levels 5 to 10. Cells (3x104/mL) were
plated in 24-well or 100-mm culture dishes in DMEM, supplemented as
described above, and allowed to grow to subconfluence for 24 to 48
hours, after which they were preincubated in DMEM containing 0.5% FCS
and supplemented with insulin (5 µg/mL) and transferrin (5 µg/mL)
for 24 hours and used for the experiments described below.
This investigation was performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication 85-23, revised 1985).
Measurements of Nitrite
NO production by the cultured cells was determined by
measurement of the nitrite contents of the culture
medium.25 VSMCs plated in 24-well dishes were incubated in
DMEM containing 0.5% FCS at 37°C. The nitrite contents of culture
media were determined by mixing 500 µL of medium with an equal volume
of Griess reagent (1 part 0.1% naphthylethylenediamine
dihydrochloride to 1 part 1% sulfanilamide in 5% phosphoric
acid).26 The absorbance at 550 nm was measured, and the
nitrite concentration was determined by interpolation of a calibration
curve of standard sodium nitrite concentrations against absorbance.
After a washing, cells were dissolved in 0.2 mL of 1% SDS and used for
protein assay (Bio-Rad assay kit) with BSA as a standard. Nitrite
levels were corrected by protein measurement, and data are shown as
nmol/mg protein.
Assay of iNOS mRNA
Total RNA was extracted from VSMCs plated in 100-mm culture
dishes by the acid guanidinium isothiocyanatephenol-chloroform
method, and 30-µg aliquots were subjected to electrophoresis on 1%
agarose gels. After electrophoretic separation, RNA was transferred
onto nylon filters, which were then hybridized with a random-primed
[32P]-labeled mouse macrophage iNOS
cDNA probe for 24 hours,4 followed by 2 washings with an
aqueous solution of 150 mmol/L NaCl, 15 mmol/L sodium
citrate, and 0.1% SDS at 65°C. The filters were exposed to Kodak
XAR-5 film for 1 to 2 days at -70°C with 1 intensifying screen.
Assay for iNOS Protein
The expression of iNOS protein was analyzed by
immunoblotting with an anti-iNOS antibody as described
previously.27 Briefly, cells were lysed in a buffer
containing 50 mmol/L Tris/HCl (pH 7.5), 1 mmol/L EDTA, 1
µmol/L leupeptin, 1 µmol/L pepstatin A, 0.1 mmol/L PMSF,
and 1 mol/L dithiothreitol and sonicated. The homogenates
were then centrifuged at 100 000g for 20 minutes,
and the supernatants (60 µg protein) were subjected to 10% SDS-PAGE.
The separated proteins were electrophoretically transferred onto
nitrocellulose membranes, and the resultant blots were incubated with
the antiiNOS antibody for 2 hours followed by peroxidase-labeled
donkey anti-rabbit IgG for 1 hour. Peroxidase-labeled proteins were
detected with the ECL detection system (Amersham) on x-ray film; the
results were quantified by densitometric scanning.
Statistical Analysis
Data are expressed as mean±SEM of 4 samples, which
represented
3 separate experiments. Differences were
analyzed by 1-way ANOVA combined with Scheffé's test,
and a value of P<0.05 was considered to be statistically
significant.
| Results |
|---|
|
|
|---|
|
The effect of IL-1ß on nitrite production by VSMCs was
dose-dependent (Figure 2
). Addition of
homocysteine 1 mmol/L to the culture further enhanced
IL-1ßinduced nitrite production.
|
Figure 3
shows the dose-response
relationship of the effect of homocysteine on NO synthesis.
Homocysteine increased IL-1ßstimulated nitrite production
by VSMCs in a dose-dependent manner. Homocysteine by itself did not
affect the basal level of nitrite production.
|
As shown in Figure 4
, in the presence of
the NOS inhibitor L-NMMA 1 mmol/L or the RNA synthesis
inhibitor actinomycin D 5 µg/mL, the effects of
homocysteine and IL-1ß were completely abolished.
|
Effects of Homocysteine on iNOS mRNA and Protein Levels
We then examined whether homocysteine induced an increase in iNOS
mRNA accumulation in VSMCs. As shown in Figure 5
, unstimulated cells did not express
iNOS mRNA. Incubation with IL-1ß for 24 hours resulted in an
induction of iNOS mRNA expression, and its expression was further
increased in the presence of homocysteine at >0.1 mmol/L.
|
The expression of iNOS protein by homocysteine was also
analyzed by immunoblotting with the anti-iNOS
antibody (Figure 6
). No immunoreactive
band of iNOS was detected in unstimulated VSMCs. The iNOS protein band
with a molecular mass of
125 kDa appeared clearly after exposure to
IL-1ß for 24 hours, and its accumulation was further increased in the
presence of homocysteine.
|
Involvement of Oxidants in the Action of Homocysteine
We investigated the mechanism of the stimulatory effect of
homocysteine on nitrite production. Oxygen-derived molecules
such as superoxide and hydrogen peroxide generated by way of the
reactive sulfhydryl (SH) group are thought to account for the
endothelial cytotoxicity of
homocysteine.28 29 We thus investigated the involvement of
these molecules in homocysteine-induced nitrite production.
First we investigated the effect of other molecules containing the SH
group, cysteine, and glutathione. As shown in Figure 7
, both cysteine and glutathione also
enhanced nitrite production by IL-1ßstimulated VSMCs.
Furthermore, the effect of homocysteine was not maintained in the
presence of glutathione (Figure 8
).
|
|
We next examined the effect of hydrogen peroxide on nitrite
production. Addition of hydrogen peroxide dose-dependently
(0.01 to 0.1 mmol/L) increased nitrite production by
IL-1ßstimulated cells, whereas it did not affect the basal level of
nitrite production (Figure 9
).
|
We then investigated whether radical scavengers could inhibit the
effect of homocysteine. As shown in Figure 10
, addition of the radical scavenger
catalase 1000 U/mL or superoxide dismutase 1000 U/mL markedly reduced
homocysteine-induced nitrite accumulation.
|
| Discussion |
|---|
|
|
|---|
Damage to the vascular endothelium by homocysteine is
believed to be secondary to oxidative product formation
accompanying oxidation of the SH group of the amino
acid.28 29 We previously reported that the radical
scavenger catalase blocked the effect of homocysteine on
endothelial glycosaminoglycan
metabolism.21 We thus investigated the
involvement of oxygen-derived molecules in homocysteine-induced NO
production by VSMCs and found that hydrogen peroxide as well as
cysteine and glutathione also enhanced NO production, and the
radical scavenger catalase and superoxide dismutase significantly
inhibited the effect of homocysteine as well as those of cysteine and
glutathione (data not shown). Furthermore, the effect of homocysteine
was not maintained in the presence of glutathione. These results
suggest that oxidative products are involved in the action of
homocysteine, although the precise mechanism remains obscure. Welch et
al23 recently reported that homocysteine induced NO
synthesis in VSMCs by NF-
Bdependent transcriptional activation of
iNOS.
In the present study, homocysteine significantly increased IL-1ßstimulated NO production at 0.1 to 1 mmol/L. The effect of homocysteine occurred at the same concentrations as used in previous experiments.17 18 19 20 21 22 Atherosclerosis appears to be associated with homocysteine concentrations of 0.2 to 0.25 mmol/L in hyperhomocysteinemic patients, although levels of homocysteine found in the plasma of patients with vascular diseases are considerably lower than those in homozygous homocysteinemic patients.11 12 13 14 For example, the Physicians' Health Study demonstrated that patients with plasma homocysteine levels >15.8 µmol/L had a 3-fold increase in the risk of myocardial infarction.12 Whether such low levels of homocysteine could affect NO synthesis in vivo is unknown.
iNOS activity is induced in blood vessel wall and cultured VSMCs by endotoxins and cytokines.5 Joly et al6 demonstrated that in vivo balloon injury induced NOS activity in rat carotid arteries, even in the absence of endothelium. Hansson et al34 reported that arterial smooth muscle cells in the neointima formed after deendothelializing balloon injury of the rat carotid artery expressed the cytokine-inducible isoform of NOS. Buttery et al7 also reported that iNOS mRNA and protein were present within human arteriosclerotic lesions. NO production by VSMCs may in part compensate for the absence of endothelial NO synthesis by inhibiting smooth muscle cell proliferation, as well as by limiting thrombus formation by preventing platelet adhesion and aggregation.35 36 37 This hypothesis is supported by the observation in animals that L-arginine attenuates neointimal formation after balloon injury38 or that iNOS suppresses the development of allograft arteriosclerosis.39 Thus, homocysteine-induced NO may suppress the atherothrombotic risk of hyperhomocysteinemic states. However, the potential role of excess NO derived from iNOS in the vascular tissue under pathological conditions has not been fully characterized and is still controversial. NO also has toxic and cytolytic effects, and increased expression of iNOS may promote the process of atherogenesis by increasing cell death and necrosis.
In conclusion, homocysteine enhances NO synthesis in IL-1ßstimulated VSMCs, and oxidative products are involved in the effect of homocysteine. However, further studies are necessary to clarify the role of homocysteine in NO production by the vascular tissue and its involvement in the pathogenesis of vascular lesions.
| Acknowledgments |
|---|
Received June 19, 1998; revision received October 7, 1998; accepted October 26, 1998.
| References |
|---|
|
|
|---|
2.
Nathan C, Xie Q. Regulation of biosynthesis of nitric
oxide. J Biol Chem. 1994;269:1372513728.
3. Shindo T, Ikeda U, Ohkawa F, Takahashi M, Funayama H, Nishinaga M, Kawahara Y, Yokoyama M, Shimada K. Nitric oxide synthesis in rat cardiac myocytes and fibroblasts. Life Sci. 1994;55:11011108.[Medline] [Order article via Infotrieve]
4. Koide M, Kawahara Y, Tsuda T, Yokoyama M. Cytokine-induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells. FEBS Lett. 1993;318:213217.[Medline] [Order article via Infotrieve]
5.
Dinerman JL, Lowenstein CJ, Snyder SH. Molecular
mechanisms of nitric oxide regulation. Circ Res. 1993;73:217222.
6.
Joly GA, Schini VB, Vanhoutte PM. Balloon injury and
interleukin-1ß induce nitric oxide synthase activity in rat
carotid arteries. Circ Res. 1992;71:331338.
7. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996;75:7785.[Medline] [Order article via Infotrieve]
8. Mudd SH, Skovby FS, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer C. The natural history of homocystinuria due to cystathione ß-synthase deficiency. Am J Hum Genet. 1985;37:131.[Medline] [Order article via Infotrieve]
9. Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost. 1997;78:527531.[Medline] [Order article via Infotrieve]
10.
Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson
PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH.
Association between plasma homocyst(e)ine concentrations and
extracranial carotid-artery stenosis. N Engl J
Med. 1995;332:286291.
11. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:11491155.[Abstract]
12.
Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson
B, Ullmann D, Tishler PV, Henneckens CH. A prospective study of plasma
homocysteine and risk of myocardial infarction in US physicians.
J Am Med Assoc. 1992;268:877881.
13.
Mainlow MR. Hyperhomocysteinemia: a common and easily
reversible risk factor for occlusive atherosclerosis.
Circulation. 1990;81:20042006.
14. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537543.
15.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A
quantitative assessment of plasma homocysteine as a risk factor for
vascular disease: probable benefits of increasing folic acid intakes.
JAMA. 1995;274:10491057.
16. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731741.
17. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activation. J Clin Invest. 1986;77:19091916.
18.
Hayashi T, Honda G, Suzuki K. An atherogenic stimulus
homocysteine inhibits cofactor activity of thrombomodulin and enhances
thrombomodulin expression in human umbilical vein
endothelial cells. Blood. 1992;79:29302936.
19.
Rodgers GM, Conn MT. Homocysteine, an atherogenic
stimulus, reduces protein C activation by arterial and
venous endothelial cells. Blood. 1990;75:895901.
20. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:19061914.
21. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993;92:13811386.
22.
Tsai J, Perrella MA, Yoshizumi M, Hsieh C, Haber E,
Schlegel R, Lee M. Promotion of vascular smooth muscle cell growth by
homocysteine: a link to atherosclerosis. Proc
Natl Acad Sci U S A. 1994;91:63696373.
23.
Welch GN, Upchurch GR Jr, Farivar RS, Pigazzi A, Vu K,
Brecher P, Keaney JF Jr, Loscalzo J. Homocysteine-induced nitric oxide
production in vascular smooth-muscle cells by
NF-
B-dependent transcriptional activation of Nos 2. Proc
Assoc Am Physicians. 1998;110:2231.[Medline]
[Order article via Infotrieve]
24.
Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T,
Tsuruya Y, Kano S. Interleukin 6 stimulates growth of vascular smooth
muscle cells in a PDGF-dependent manner. Am J Physiol. 1991;260:H1713H1717.
25.
Ikeda U, Kanbe T, Kawahara Y, Yokoyama M, Shimada K.
Adrenomedullin augments inducible nitric oxide synthase expression in
cytokine-stimulated cardiac myocytes. Circulation. 1996;94:25602565.
26. Green LC, Wagner DA, Glogowski J, Skiper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal Biochem. 1982;126:131138.[Medline] [Order article via Infotrieve]
27.
Ikeda U, Kurosaki K, Shimpo M, Okada K, Saito T,
Shimada K. Adenosine stimulates nitric oxide synthesis in rat
cardiac myocytes. Am J Physiol. 1997;273:H59H65.
28. Wall RT, Horlan JM, Harker LA, Striker GE. Homocyst(e)ine-induced endothelial injury in vitro: a model for the study of vascular injury. Thromb Res. 1980;18:113121.[Medline] [Order article via Infotrieve]
29. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocyst(e)ine. J Clin Invest. 1986;77:13701376.
30.
Lentz SR, Sadler JE. Homocysteine inhibits von
Willebrand factor processing and secretion by preventing
transport from the endoplasmic reticulum. Blood. 1993;81:683689.
31. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993;91:28732879.
32. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308318.
33. Tsai J, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, Haber E, Chang TH, Schlegel R, Lee M. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146153.[Medline] [Order article via Infotrieve]
34.
Hansson GK, Geng Y, Holm J, Hårdhammar P, Wennmalm Å,
Jennische E. Arterial smooth muscle cells express nitric
oxide synthase in response to endothelial injury.
J Exp Med. 1994;180:733738.
35. Wennmalm Å. Endothelial nitric oxide and cardiovascular disease. J Intern Med. 1994;235:317327.[Medline] [Order article via Infotrieve]
36. Lloyd-Jones D, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 1996;47:365375.[Medline] [Order article via Infotrieve]
37.
Yan Z, Yokota T, Zhang W, Hansson GK. Expression of
inducible nitric oxide synthase inhibits platelet adhesion and
restores blood flow in the injured artery. Circ Res. 1996;79:3844.
38.
Hamon M, Vallet B, Bauters C, Wernert N, McFadden EP,
Lablanche JM, Dupuis B, Bertrand ME. Long-term oral administration of
L-arginine reduces intimal thickening and enhances
neoendothelium-dependent acetylcholine-induced
relaxation after arterial injury. Circulation. 1994;90:13571362.
39. Shears II LL, Kawaharada N, Tzeng E, Billiar TR, Watkins SC, Kovesdi I, Lizonova A, Pham SM. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest. 1997;100:20352042.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
I. Qureshi, H. Chen, A. T Brown, R. Fitzgerald, X. Zhang, J. Breckenridge, R. Kazi, A. J Crocker, M. C Stuhlingexsr, K. Lin, et al. Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor Vascular Medicine, August 1, 2005; 10(3): 215 - 223. [Abstract] [PDF] |
||||
![]() |
S. Kishi, J. Griener, C. Cheng, S. Das, E. H. Cook, D. Pei, M. Hudson, J. Rubnitz, J. T. Sandlund, C.-H. Pui, et al. Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia J. Clin. Oncol., August 15, 2003; 21(16): 3084 - 3091. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Ikeda, Y. Maeda, K. Yamamoto, and K. Shimada C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes Cardiovasc Res, October 1, 2002; 56(1): 86 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wang, Y. L. Siow, and K. O Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF-{kappa}B in THP-1 macrophages Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2840 - H2847. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Crott and M. Fenech Preliminary study of the genotoxic potential of homocysteine in human lymphocytes in vitro Mutagenesis, May 1, 2001; 16(3): 213 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, U. Ikeda, M. Shimpo, M. Ikeda, S. Minota, and K. Shimada Fluvastatin Upregulates Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Vascular Smooth Muscle Cells Hypertension, December 1, 2000; 36(6): 923 - 928. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Detmers, M. Hernandez, J. Mudgett, H. Hassing, C. Burton, S. Mundt, S. Chun, D. Fletcher, D. J. Card, J. Lisnock, et al. Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice J. Immunol., September 15, 2000; 165(6): 3430 - 3435. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |